Special Issue

Stem Cells in Oncology: Emerging Targets for Therapy

Message from the Guest Editors

Cancer treatment is a challenging task; thus, current therapeutics must be improved in order to achieve better outcomes. Understanding tumorigenesis would aid in the development of drugs for cancer treatment: however, the resistance developed by cancer cells after cancer therapies must be overcome. A distinguishing characteristic of cancer stem cells (CSCs) is that they cause relapse in solid as well as liquid tumors after remission, and recent studies have shown that CSCs can develop resistance against the cancer immunotherapy. Understanding the mechanisms implicated in the formation, self-renewal, quiescence. and adaptability of CSCs would enable the development of a multidirectional strategy for targeting and eradicating cancer stem cells. CSCs interact with tumor microenvironments in a reciprocal manner, thus playing a significant role in the development of cancer. A comprehensive understanding of the interaction between the tumor microenvironment and CSCs would enable CSCs to be targeted, inhibiting stemness and quiescence, overcoming treatment resistance, and increasing immune sensitivity.

Guest Editors

Dr. Ling Li

Department of Hematologic Malignancies Translational Science, City of Hope Medical Center, Duarte, CA, USA

Dr. Umesh P Yadav

Department of Hematological Malignancy Translational Science, City of Hope Medical Center, Duarte, CA, USA

Deadline for manuscript submissions

31 March 2026



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/232757

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

